C1M has potential as a biomarker

The earlier rheumatoid arthritis (RA) is diagnosed, the better the prognosis. But easier said than done. Conventional clinical, serological and imaging markers often lack sufficient sensitivity in the early stages of the disease, which limits their prognostic value. But there could be a new option: French researchers found evidence that C1M, a serum biomarker for type I collagen degradation, can help predict radiographic progression of early RA.